{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:04:34Z","timestamp":1790730274640,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was supported by an unrestricted grant from Gilead Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Preventing disease progression and viral suppression are the main goals of antiviral therapy in chronic hepatitis B (CHB). Liver stiffness measurement (LSM) by transient elastography is a reliable non-invasive method to assess liver fibrosis in patients with CHB. Our aim was to explore factors that may affect changes in LSMs during long term tenofovir (TDF) monotherapy in a well characterized cohort of patients with compensated CHB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed serial LSMs in 103 adult patients with CHB who were on TDF monotherapy and had at least three LSMs over a period of 90 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-five (24%) patients had advanced fibrosis at baseline. A significant decline in mean LSM between baseline and last visit (8.7\u2009\u00b1\u20096.2\u00a0kPa vs. 6.7\u2009\u00b1\u20093.3, <jats:italic>p<\/jats:italic>\u2009=\u200910<jats:sup>\u2212\u20093<\/jats:sup>) was observed. Twenty-four (23%) patients had progression of liver fibrosis with mean increase in liver stiffness of 2.8\u00a0kPa (range: 0.2\u201310.2\u00a0kPa). Multivariate analysis showed that BMI\u2009\u2265\u200925 (OR, 0.014; 95% CI, 0.001\u20130.157; <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and advanced fibrosis (OR, 5.169; 95% CI, 1.240\u201321.540; <jats:italic>p<\/jats:italic>\u2009=\u20090.024) were independently associated with a fibrosis regression of &gt;\u200930% of liver stiffness compared to baseline value.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In CHB patients TDF monotherapy resulted in liver fibrosis regression, especially in patients with advanced fibrosis. Despite the successful antiviral effect of TDF, 1 out of 4 patients had liver fibrosis progression. Obesity and advanced fibrosis at baseline were independently associated with significant liver fibrosis regression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03200-3","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T11:02:03Z","timestamp":1712919723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. A retrospective - prospective multicenter study"],"prefix":"10.1186","volume":"24","author":[{"given":"Hariklia","family":"Kranidioti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Zisimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Oikonomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Voulgaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Siakavellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polixeni","family":"Agorastou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Triantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spilios","family":"Manolakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"3200_CR1","unstructured":"Progress report on HIV, viral hepatitis and sexually transmitted infections. Accountability for the global health sector strategies, 2016\u20132021. World Health Organization; 2019."},{"issue":"3","key":"3200_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678\u201386.","journal-title":"Gastroenterology"},{"issue":"3","key":"3200_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3350\/cmh.2014.20.3.228","volume":"20","author":"GL Wong","year":"2014","unstructured":"Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol. 2014;20(3):228\u201336.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"3200_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"8","key":"3200_CR5","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/135965350701200816","volume":"12","author":"MF Yuen","year":"2007","unstructured":"Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 2007;12(8):1295\u2013303.","journal-title":"Antivir Ther"},{"issue":"9865","key":"3200_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468\u201375.","journal-title":"Lancet"},{"issue":"3","key":"3200_CR7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jhep.2009.05.031","volume":"51","author":"S Manolakopoulos","year":"2009","unstructured":"Manolakopoulos S, Triantos C, Theodoropoulos J, Vlachogiannakos J, Kougioumtzan A, Papatheodoridis G, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol. 2009;51(3):468\u201374.","journal-title":"J Hepatol"},{"issue":"2","key":"3200_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","volume":"53","author":"GV Papatheodoridis","year":"2010","unstructured":"Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53(2):348\u201356.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"3200_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/liv.12710","volume":"35","author":"P Bedossa","year":"2015","unstructured":"Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int. 2015;35(Suppl 1):78\u201381.","journal-title":"Liver Int"},{"issue":"2","key":"3200_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3350\/cmh.2012.18.2.163","volume":"18","author":"KS Jung","year":"2012","unstructured":"Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol. 2012;18(2):163\u201373.","journal-title":"Clin Mol Hepatol"},{"issue":"9","key":"3200_CR11","doi-asserted-by":"publisher","first-page":"e44930","DOI":"10.1371\/journal.pone.0044930","volume":"7","author":"YE Chon","year":"2012","unstructured":"Chon YE, Choi EH, Song KJ, Park JY, Kim DY, Han KH, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS ONE. 2012;7(9):e44930.","journal-title":"PLoS ONE"},{"issue":"7","key":"3200_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/jvh.12176","volume":"21","author":"GV Papatheodoridis","year":"2014","unstructured":"Papatheodoridis GV, Manolakopoulos S, Margariti A, Papageorgiou MV, Kranidioti H, Katoglou A, et al. The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat. 2014;21(7):517\u201324.","journal-title":"J Viral Hepat"},{"issue":"8","key":"3200_CR13","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/liv.12377","volume":"34","author":"MN Kim","year":"2014","unstructured":"Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. Liver Int. 2014;34(8):1216\u201323.","journal-title":"Liver Int"},{"issue":"7","key":"3200_CR14","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1111\/j.1365-2893.2010.01428.x","volume":"18","author":"J Fung","year":"2011","unstructured":"Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. J Viral Hepat. 2011;18(7):e200\u20135.","journal-title":"J Viral Hepat"},{"issue":"8","key":"3200_CR15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.dld.2018.05.005","volume":"50","author":"A Facciorusso","year":"2018","unstructured":"Facciorusso A, Garcia Perdomo HA, Muscatiello N, Buccino RV, Wong VW, Singh S. Systematic review with meta-analysis: change in liver stiffness during anti-viral therapy in patients with hepatitis B. Dig Liver Dis. 2018;50(8):787\u201394.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"3200_CR16","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.14309\/ajg.0000000000001239","volume":"116","author":"D Ji","year":"2021","unstructured":"Ji D, Chen Y, Shang Q, Liu H, Tan L, Wang J, et al. Unreliable estimation of Fibrosis Regression during treatment by liver stiffness measurement in patients with chronic Hepatitis B. Am J Gastroenterol. 2021;116(8):1676\u201385.","journal-title":"Am J Gastroenterol"},{"key":"3200_CR17","doi-asserted-by":"crossref","unstructured":"The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017. Hepatology. 2017;66(S1):1\u20131185.","DOI":"10.1002\/hep.29634"},{"key":"3200_CR18","doi-asserted-by":"crossref","unstructured":"Abstracts of the 27th Annual Conference of APASL, March 14-18, 2018, New Delhi, India. Hepatol Int. 2018:181\u2013661.","DOI":"10.1007\/s12072-018-9852-3"},{"key":"3200_CR19","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guideline P, Chair, representative EGB, Panel m. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659\u201389.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"3200_CR20","doi-asserted-by":"crossref","unstructured":"Xu W, Hu Q, Chen C, Li W, Li Q, Chen L. Non-invasive Assessment of Liver Fibrosis Regression in Patients with Chronic Hepatitis B: A Retrospective Cohort Study. Infect Dis Ther. 2023;12(2):487\u201398.","DOI":"10.1007\/s40121-022-00738-1"},{"key":"3200_CR21","doi-asserted-by":"crossref","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959\u201374.","DOI":"10.1007\/978-3-031-08552-9"},{"key":"3200_CR22","doi-asserted-by":"crossref","unstructured":"Chon YE, Park JY, Myoung SM, Jung KS, Kim BK, Kim SU, et al. Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. Am J Gastroenterol. 2017;112(6):882\u201391.","DOI":"10.1038\/ajg.2017.93"},{"key":"3200_CR23","doi-asserted-by":"crossref","unstructured":"Cho H, Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, et al. Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study. BMC Gastroenterol. 2023;23(1):210.","DOI":"10.1186\/s12876-023-02846-9"},{"key":"3200_CR24","doi-asserted-by":"crossref","unstructured":"Chon YE, Jung KS, Ha Y, Kim MN, Lee JH, Hwang SG, et al. High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis. J Viral Hepat. 2020;27(11):1119\u201326.","DOI":"10.1111\/jvh.13345"},{"key":"3200_CR25","doi-asserted-by":"crossref","unstructured":"Seto WK, Fung J, Cheung KS, Mak LY, Hui RW, Liu KS, et al. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016;44(10):1071-9.","DOI":"10.1111\/apt.13804"},{"key":"3200_CR26","doi-asserted-by":"crossref","unstructured":"Shen F, Mi YQ, Xu L, Liu YG, Wang XY, Pan Q, et al. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Aliment Pharmacol Ther. 2019;50(1):93\u2013102.","DOI":"10.1111\/apt.15298"},{"key":"3200_CR27","doi-asserted-by":"crossref","unstructured":"Liu J, Ma Y, Han P, Wang J, Liu YG, Shi RF, et al. Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients. Clin Res Hepatol Gastroenterol. 2022;46(8):101957.","DOI":"10.1016\/j.clinre.2022.101957"},{"key":"3200_CR28","doi-asserted-by":"crossref","unstructured":"Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64(4):773\u201380.","DOI":"10.1016\/j.jhep.2015.11.012"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03200-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T11:03:53Z","timestamp":1712919833000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03200-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3200"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03200-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"18 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics committee of the participating centers (General Hospital of Athens \u201cHippocration\u201d, General Hospital of Thessaloniki \u201cHippocration\u201d, University of Patras, General Hospital of Athens \u201cLaiko\u201d) and was conducted according to the principles of the Declaration of Helsinki. The requirement for informed consent was waived by the Ethics Committee of the centers because we collected retrospectively, in the majority of the patients, ordinary clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.A: lecturer for Gilead and AbbVie, M.D: lecturer for Gilead, C.T.: lectures\/research\/conference coverage by MSD, Roche, Abbvie, Bristol-Myers Squibb, Bayer, Janssen and Gilead Sciences, I.G. has received grants from Gilead, G.P.: advisor\/lecturer for Abbvie, Amgen, Dicerna, Gilead, GlaxoSmithKline, Ipsen, Janssen, Merck Sharp & Dohme, Novo Nordisk, Roche and Takeda; research grants from Abbvie and Gilead, S.M.: advisor\/lecturer for Abbvie, Gilead, Ipsen, Merck Sharp & Dohme, Roche, Integris and Genesis; research grants from Abbvie and Gilead. For the remaining authors, there are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}